Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease

Inclusion Criteria: * Age ≥18 years at the time of informed consent. * Diagnosis of chronic coronary syndrome (CCS) according to ESC guidelines. * Undergoing successful PCI with implantation of one or more new-generation drug-eluting stents (DES). * Indication for dual antiplatelet therapy (DAPT) following PCI. * Willingness and ability to comply with all study procedures and follow-up assessments. * Signed informed consent prior to any study-specific procedure. * Creatinine clearance ≥30 mL/min, calculated using the Cockcroft-Gault formula. * Life expectancy greater than 1 year in the investigator's judg-ment. * Hemodynamically stable at the time of randomization. * Acceptable bleeding risk profile: patients fulfilling ARC-HBR criteria may be included only if the treating physician deems a 6-month antiplatelet regimen to be safe. * No contraindications to study drugs, including aspirin, clopi-dogrel, or ticagrelor. Exclusion Criteria: * Presentation with acute coronary syndrome (ACS), including STEMI, NSTEMI, or unstable angina within the previous 6 mon-ths. * Planned staged PCI or revascularization procedure within 6 months after index PCI. * Requirement for long-term oral anticoagulation therapy, such as for atrial fibrillation, mechanical heart valves, or venous thromboembolism. * History of major bleeding, including gastrointestinal or intra-cranial bleeding, within the past 6 months. * Severe hepatic impairment, active liver disease, or transamina-ses \>3× upper limit of normal. * Known platelet disorder, coagulopathy, or thrombocytopenia (\<100,000/mm³). * Contraindication or hypersensitivity to aspirin, clopidogrel, or ticagrelor, or known drug interaction that precludes their use. * Ongoing active bleeding or high risk of bleeding that, in the opinion of the investigator, precludes DAPT. * Pregnancy or breastfeeding, or women of childbearing potential who are not using effective contraception. * Life expectancy \<1 year due to non-cardiovascular comorbidi-ties (e.g., cancer, advanced renal failure). * Participation in another interventional clinical trial that may interfere with the outcomes of this study. * Severe anemia (hemoglobin \<9 g/dL) not corrected before ran-domization. * Inability or unwillingness to provide informed consent or ad-here to study follow-up. * Prior stroke with residual neurological deficit or history of di-sabling stroke (mRS ≥3).